Novo Nordisk settles Minnesota insulin pricing case

Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data ...
J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
ST. PAUL, Minn. – All Minnesotans, whether they have insurance or not, will be able to buy insulin products for $35 a month ...
In an important regulatory win for Denmark’s Novo Nordisk, the US Food and Drug Administration (FDA) yesterday approved ...
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
French drugmaker Sanofi reported a fourth-quarter profit that came in-line with analysts' estimates on Thursday, and said it would buy back 5 billion euros ($5.21 billion) in shares this year as it ...
A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...